← 4D Molecular Therapeutics, Inc. (FDMT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
4D Molecular Therapeutics, Inc. (FDMT)
Biological Products, (No Diagnostic Substances) · market cap $819M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
12
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
4D Molecular Therapeutics (FDMT) is a clinical-stage biologics company with 227 employees and a ~$647M market cap, focused primarily on ocular gene therapy. Its lead proprietary asset is 4D-150 IVT, an intravitreal gene therapy in Phase 3 for neovascular AMD and Phase 2 for diabetic macular edema, alongside a broader pipeline spanning retinal diseases, cystic fibrosis, and Fabry disease. The company holds only ~$72.5M in cash against a stated 3.2-month runway, making near-term financing a structural imperative.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 3 · 4D-150 IVT (3E10 vg/eye)imp 9/10
- 2027-06-15 (est.)Phase 2 · 4D-710imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 4D-150 IVT | Phase 2 | Diabetic Macular Edema |
| 4D-150 IVT (3E10 vg/eye) | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) |
| 4D-125 IVT Injection | Phase 2 | X-Linked Retinitis Pigmentosa |
| 4D-310 | Phase 2 | Fabry Disease |
| 4D-710 | Phase 2 | Cystic Fibrosis Lung |
| 11C-choline Injection | Phase 3 | Metastatic Prostate Cancer |
| 99mTc-glucarate solution | Phase 2 | Acute Coronary Syndrome |
| AMT-101 (oral) | Phase 2 | Ulcerative Colitis |
| [F 18]HX4 | Phase 2 | Head and Neck Cancer |
| [F-18]RGD-K5 | Phase 2 | Metastatic Breast Cancer |
| [F-18] FMISO | Phase 2 | Head and Neck Cancer |
| AMT-101 (oral)-Dose A | Phase 2 | Pouchitis |
Price & technical context
3-month
+6.5%
6-month
+40.2%
12-month
+59.3%
52-wk range
$7.19–$16.76
vs 50-day MA
+3.7%
vs 200-day MA
+32.7%
Realized vol
78.6%
Max drawdown
-85.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for FDMT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.